{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=22&sponsor=AstraZeneca",
    "query": {
      "sponsor": "AstraZeneca",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 1904,
    "total_pages": 191,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=23&sponsor=AstraZeneca&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=21&sponsor=AstraZeneca&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T03:11:33.426Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03308396",
      "title": "Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Kidney Cancer",
        "Kidney Cancer",
        "Clear Cell Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Guadecitabine",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ajjai Alva, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2017-12-19",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2022-02-17",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03308396"
    },
    {
      "nct_id": "NCT07015697",
      "title": "A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent or Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2025-07-17",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 6,
      "location_summary": "Newport Beach, California • Atlanta, Georgia • Las Vegas, Nevada + 3 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Maumee",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07015697"
    },
    {
      "nct_id": "NCT04003246",
      "title": "Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Lung Cancer Stage III"
      ],
      "interventions": [
        {
          "name": "Thoracic RT and Durvalumab",
          "type": "RADIATION"
        },
        {
          "name": "Consolidative Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2020-04-03",
      "completion_date": "2024-11-05",
      "has_results": true,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04003246"
    },
    {
      "nct_id": "NCT05648110",
      "title": "Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19, SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "AZD5156 (Parent study Sentinel Safety Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Parent study Sentinel Safety Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EVUSHELD™ (Parent study Main Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD3152 (Parent study Main Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Parent study Main Cohort)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD3152 (Sub-study)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 - EVUSHELD™ (Sub-study)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "12 Years to 130 Years"
      },
      "enrollment_count": 3882,
      "start_date": "2022-12-16",
      "completion_date": "2025-02-11",
      "has_results": true,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 130,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05648110"
    },
    {
      "nct_id": "NCT01042977",
      "title": "Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Cardiovascular Disease",
        "Inadequate Glycaemic Control"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 964,
      "start_date": "2010-03",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-02-17",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 54 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01042977"
    },
    {
      "nct_id": "NCT06147830",
      "title": "A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Major Bleeding"
      ],
      "interventions": [
        {
          "name": "None (Observational study)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 2202,
      "start_date": "2023-12-04",
      "completion_date": "2024-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-03",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 25,
      "location_summary": "Chandler, Arizona • Orange, California • Sacramento, California + 22 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06147830"
    },
    {
      "nct_id": "NCT06067828",
      "title": "A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Treatment B: Budesonide and Formoterol Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Treatment C : Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 171,
      "start_date": "2023-10-24",
      "completion_date": "2026-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Tarzana, California • Torrance, California + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Anderson",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06067828"
    },
    {
      "nct_id": "NCT03682068",
      "title": "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unresectable Locally Advanced Urothelial Cancer",
        "Metastatic Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin + Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1246,
      "start_date": "2018-09-27",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Salinas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682068"
    },
    {
      "nct_id": "NCT03979313",
      "title": "A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "MEDI8897",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "0 Years to 1 Year"
      },
      "enrollment_count": 3012,
      "start_date": "2019-07-23",
      "completion_date": "2023-03-21",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 66,
      "location_summary": "Birmingham, Alabama • Fort Defiance, Arizona • Fayetteville, Arkansas + 59 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Defiance",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03979313"
    },
    {
      "nct_id": "NCT01929629",
      "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gonococcal (GC) Infection"
      ],
      "interventions": [
        {
          "name": "Part A",
          "type": "DRUG"
        },
        {
          "name": "Part B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2013-09",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-04-15",
      "last_synced_at": "2026-10-29T03:11:33.426Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01929629"
    }
  ]
}